RBC Upgrades Rigel Pharmaceuticals (RIGL) to Sector Perform
More News related to RIGL
- Rigel Announces Third Quarter 2009 Financial Results
- Rigel Announces Presentations at Two Investor Conferences
- Rigel to Webcast Analyst Briefing on October 20, 2009
- Rigel Pharma (RIGL) Prices 13M Shares at $7.25
- Rigel Announces Pricing of Public Offering of 13,000,000 Shares of Common Stock
RBC upgrades Rigel Pharmaceuticals (Nasdaq: RIGL) from Underperform to Sector Perform.
Rigel Pharmaceuticals, Inc. (Rigel) is a clinical-stage drug development company that discovers and develops small molecule drugs for the treatment of inflammatory/autoimmune diseases, as well as for certain cancers and metabolic diseases.
To see more analyst ratings on RIGL Click Here.
Related Categories
UpgradesStocks Mentioned
+0.14Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
